InhaleRx Limited (NX1) AI Stock Analysis

InhaleRx Limited has secured strong shareholder backing at its 29 January general meeting, with all eight resolutions passed by poll, including the ratification of prior share issues, approvals for additional placement securities and options under an...

InhaleRx Limited has scheduled a general meeting for shareholders to be held online at 4:00pm AEDT on Thursday, 29 January 2026. The meeting will cover eight resolutions to be decided by poll, with procedures outlined for virtual attendees to raise I...

InhaleRx reported progress across its clinical portfolio for the quarter ended 31 December 2025, underpinned by fresh funding and preparation for key trials. The company raised $857,730 through a placement and entitlement offer to support operating c...

InhaleRx Limited reported its quarterly cash flow for the period ended 31 December 2025, showing net operating cash outflows of A$628,000 for the quarter and A$899,000 year-to-date, largely driven by research and development and administrative expens...

InhaleRx Limited has completed the first tranche of its equity placement, receiving a final $172,500 and issuing 6.9 million ordinary shares at $0.025 each, bringing total funds raised under Tranche 1 to $600,000 before costs as part of a broader $75...

InhaleRx Limited has called an online-only general meeting of shareholders for 4:00pm AEDT on 29 January 2026, with investors able to watch, ask questions and vote via a virtual platform. The company is urging shareholders to pre-register for the web...

InhaleRx Limited has issued a proxy voting form and instructions for shareholders ahead of its general meeting scheduled for 4:00pm (AEDT) on Thursday, 29 January 2026, to be held virtually. The materials outline how shareholders can appoint proxies,...

InhaleRx Limited has called a virtual general meeting of shareholders for 29 January 2026 to consider a series of capital-raising related resolutions. The agenda includes ratification of prior share issues and Tranche 1 placement shares, approval to...

InhaleRx Limited has disclosed a change in the indirect interests of director Dr Ronald Wise following his participation in the company’s recent entitlement offer. Through beneficiary interests in Sassey Pty Ltd entities, Dr Wise acquired 113,3...

InhaleRx Limited has disclosed a change in the indirect holdings of director Sean Williams following his participation in the company’s recent entitlement offer. Williams holds his interests through TG Advisory Pty Ltd as trustee for the Willia...

InhaleRx has closed its pro-rata non-renounceable entitlement offer, raising $107,730 before costs from applications for 4.3 million new shares and associated options, below the maximum possible amount and leaving a shortfall of approximately $139,93...

InhaleRx Limited has notified the market of a new issue of unquoted equity securities, consisting of 2,154,603 deferred options (IRXAK) expiring on 22 December 2027. The options, which were previously flagged to the market, are not quoted and are not...

InhaleRx Limited has applied to the ASX for quotation of 4,309,185 new fully paid ordinary shares under its IRX ticker. The issuance of these securities, previously flagged in an Appendix 3B, will expand the company’s quoted share base and may...

InhaleRx Limited has issued 17,100,000 ordinary shares without disclosure to investors, in compliance with the Corporations Act. This move is part of their strategy to accelerate the development of their inhaled therapies, which could significantly i...

InhaleRx Limited has released a presentation providing summary information about its current activities, emphasizing its focus on innovative therapies for pain management and mental health. The presentation serves informational purposes and cautions...

InhaleRx Limited has announced the quotation of 17,100,000 fully paid ordinary securities on the ASX, as part of a previously disclosed transaction. This move is expected to enhance the company’s financial flexibility and potentially strengthen...

InhaleRx Limited has issued 17,100,000 ordinary shares at $0.025 each, raising $427,500 as part of a larger capital raise effort of up to $1,000,000. The placement, managed by Peak Asset Management, involves professional and sophisticated investors a...

InhaleRx Limited has announced a non-renounceable pro-rata entitlement offer to raise approximately $250,000, offering 1 new share for every 22 shares held at 2.5 cents per share, along with free attaching options. The offer is restricted to sharehol...

InhaleRx Limited has announced the dispatch of its Entitlement Offer Prospectus, opening the offer for subscription to eligible shareholders. The offer is part of the company’s strategy to fund the development of its inhaled therapies, with sig...

InhaleRx Limited has secured an additional $12.6 million in funding from the Linlithgow Family Office to advance the development of its SRX-25 drug, a new oral therapy targeting treatment-resistant depression. This funding will support manufacturing,...

InhaleRx Limited has announced a proposed issue of 6,000,000 unlisted options with an exercise price of $0.042, set to expire on December 22, 2027. This strategic move is intended to strengthen the company’s financial position and support its o...

InhaleRx Limited announced a proposed issue of securities, including 15 million unlisted options and 30 million ordinary fully paid shares, set to be issued on November 28, 2025. This strategic move is expected to bolster the company’s financia...

InhaleRx Limited has announced a proposed issuance of securities, including 4,953,367 unlisted options and 9,906,734 ordinary fully paid shares. This move, set to take place in December 2025, is part of a standard pro rata issue, which is non-renounc...

InhaleRx Limited has announced a non-renounceable entitlement offer to its eligible shareholders, allowing them to purchase up to 9,906,734 new shares at a price of $0.025 per share. This offer, scheduled to open on December 5, 2025, and close on Dec...

InhaleRx Limited has announced the addition of SRX-25, a ketamine-based oral fixed-dose drug, to its development pipeline, targeting treatment-resistant depression (TRD). This new formulation aims to improve patient access and adherence by offering a...

InhaleRx Limited has requested a trading halt on its securities pending an announcement related to a new drug development program and associated capital raising. This move is intended to manage the company’s continuous disclosure obligations an...

InhaleRx Limited has announced the issuance of 1,000,000 performance rights and 500,000 options as part of its employee incentive scheme. This strategic move is aimed at enhancing employee engagement and aligning their interests with the company&#821...